DJ Ocugen's CEO Shankar Musunuri on Q1 2021 Results -- Earnings Call Transcript >OCGN
Dow Jones · 1d ago
Cantor Fitzgerald Downgrades Ocugen to Neutral, Lowers Price Target to $11
Cantor Fitzgerald analyst Kristen Kluska downgrades Ocugen (NASDAQ:OCGN) from Overweight to Neutral and lowers the price target from $15 to $11.
Benzinga · 2d ago
Ocugen (OCGN) Miss Earnings & Revenues Estimates in Q1
Zacks · 2d ago
Regional Health Properties, Auris Medical leads healthcare gainers; ChemoCentryx, Orphazyme among major losers
Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aurinia Pharmaceuticals (AUPH) ...
Seekingalpha · 2d ago
Thinking about buying stock in Acasti Pharma, Ocugen, Castor Maritime, Naked Brand, or Auris Medical?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACST, OCGN, CTRM, NAKD, and EARS.
PR Newswire - PRF · 2d ago
Ocugen slips after Q1 results shows rising costs amid progress in COVID-19 vaccine front
Ocugen ([[OCGN]] -18.8%) has lost double-digits in percentage terms for the fourth consecutive day after the company’s Q1 2021 earnings came worse than expected as R&D costs and G&A expenses
Seekingalpha · 2d ago
--Cantor Fitzgerald Downgrades Ocugen to Neutral From Overweight, Adjusts PT to $11 From $15
MT Newswires · 2d ago
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 2d ago
Ocugen EPS misses by $0.02
Ocugen (OCGN): Q1 GAAP EPS of -$0.04 misses by $0.02.Shares +5%.Ocugen’s cash, cash equivalents, and restricted cash totaled $44.9 million as of March 31, 2021, compared to $24.2 million as of December 31, 2020.Press Release
Seekingalpha · 2d ago
BRIEF-Ocugen Q1 Loss Per Share $0.04 · 2d ago
Ocugen Q1 EPS $(0.04) Up From $(0.07) YoY
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.04) per share. This is a 42.86 percent increase over losses of $(0.07) per share from the same period last year.
Benzinga · 2d ago
Ocugen Provides Business Update and First Quarter 2021 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization)Master File submitted for U.S. Food and Drug Administration review prior to a planned Emergency Use Authorizatio...
GlobeNewswire · 2d ago
Ocugen Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 7, 2021 / Ocugen Inc (NASDAQ:OCGN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 7, 2021 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the c...
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume.
Benzinga · 2d ago
Ocugen Narrows Loss in Q1
MT Newswires · 2d ago
Earnings Scheduled For May 7, 2021
  Companies Reporting Before The Bell • Cronos Group (NASDAQ:CRON) is likely to report earnings for its first quarter.
Benzinga · 2d ago
BioCryst Shares Trading Higher As Q1 Sales Beat Was Supported By Orladeyo Revenues
View more earnings on BCRXSee more from BenzingaClick here for options trades from BenzingaOcugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal StudyTherapeuticsMD Shares Plunge On Dec...
Benzinga · 3d ago
Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study
Benzinga · 3d ago
Thinking about buying stock in Nemaura Medical, Ocugen, Ambev, Precipio, or Vaxart?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NMRD, OCGN, ABEV, PRPO, and VXRT.
PR Newswire - PRF · 3d ago
Drug/Biotech Stock Q1 Earnings on May 7: RDUS, CRON & OCGN
Zacks · 3d ago
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).